Aligos Therapeutics (ALGS)
Aligos Therapeutics on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
707K
Short interest
settlement 2026-10-15
21.7
Days to cover
+7.4 days vs prior
17.1%
Short share of volume
2026-11-02
932
Fails to deliver
settlement 2026-10-13
Thu 5 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in ALGS is 707,471 shares, up 9,788 shares over the last month. Over the last 48 readings it ranged from 121,295 shares (31 October 2024) to 835,744 shares (30 April 2025). At the reported average volume of 33K shares a day that is 21.7 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/algs" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 707,471 | -0.2% | 32,549 | 21.74 |
| 2026-09-30 | 708,744 | +1.6% | 49,392 | 14.35 |
| 2026-09-15 | 697,683 | +7.6% | 45,449 | 15.35 |
| 2026-08-31 | 648,568 | +14.2% | 68,891 | 9.41 |
| 2026-08-14 | 568,056 | -6.3% | 209,382 | 2.71 |
| 2026-07-31 | 606,525 | +16.3% | 94,945 | 6.39 |
| 2026-07-15 | 521,416 | -4.0% | 514,195 | 1.01 |
| 2026-06-30 | 543,337 | -11.2% | 68,442 | 7.94 |
| 2026-06-15 | 611,712 | +6.0% | 99,837 | 6.13 |
| 2026-05-29 | 576,909 | +7.8% | 121,404 | 4.75 |
| 2026-05-15 | 535,177 | +9.3% | 155,219 | 3.45 |
| 2026-04-30 | 489,633 | +77.6% | 681,214 | 1.00 |
| 2026-04-15 | 275,689 | -10.0% | 60,560 | 4.55 |
| 2026-03-31 | 306,176 | +3.8% | 40,337 | 7.59 |
| 2026-03-13 | 294,842 | +1.7% | 45,736 | 6.45 |
| 2026-02-27 | 289,814 | +0.4% | 25,044 | 11.57 |
| 2026-02-13 | 288,715 | -1.7% | 53,738 | 5.37 |
| 2026-01-30 | 293,582 | +9.2% | 84,739 | 3.46 |
| 2026-01-15 | 268,943 | +11.7% | 75,108 | 3.58 |
| 2025-12-31 | 240,691 | -6.8% | 51,173 | 4.70 |
| 2025-12-15 | 258,242 | +14.1% | 88,675 | 2.91 |
| 2025-11-28 | 226,418 | -3.0% | 81,621 | 2.77 |
| 2025-11-14 | 233,534 | +2.8% | 80,364 | 2.91 |
| 2025-10-31 | 227,276 | -3.3% | 93,262 | 2.44 |
| 2025-10-15 | 235,005 | -13.8% | 97,157 | 2.42 |
| 2025-09-30 | 272,621 | -6.8% | 76,792 | 3.55 |
| 2025-09-15 | 292,427 | -6.3% | 50,501 | 5.79 |
| 2025-08-29 | 312,192 | +3.2% | 99,071 | 3.15 |
| 2025-08-15 | 302,609 | -16.4% | 57,904 | 5.23 |
| 2025-07-31 | 361,738 | -7.7% | 72,359 | 5.00 |
| 2025-07-15 | 391,884 | -26.5% | 91,185 | 4.30 |
| 2025-06-30 | 533,025 | -1.7% | 97,183 | 5.48 |
| 2025-06-13 | 542,118 | -1.9% | 162,100 | 3.34 |
| 2025-05-30 | 552,791 | -13.7% | 118,486 | 4.67 |
| 2025-05-15 | 640,196 | -23.4% | 197,756 | 3.24 |
| 2025-04-30 | 835,744 | +0.5% | 99,759 | 8.38 |
| 2025-04-15 | 831,999 | +1.0% | 245,352 | 3.39 |
| 2025-03-31 | 823,551 | +3.5% | 114,395 | 7.20 |
| 2025-03-14 | 795,342 | +10.1% | 187,092 | 4.25 |
| 2025-02-28 | 722,352 | +1.3% | 204,826 | 3.53 |
| 2025-02-14 | 712,993 | +23.7% | 275,388 | 2.59 |
| 2025-01-31 | 576,358 | -13.3% | 251,513 | 2.29 |
| 2025-01-15 | 664,384 | +11.2% | 427,046 | 1.56 |
| 2024-12-31 | 597,297 | +30.7% | 485,625 | 1.23 |
| 2024-12-13 | 457,104 | +61.1% | 416,785 | 1.10 |
| 2024-11-29 | 283,759 | -2.7% | 549,475 | 1.00 |
| 2024-11-15 | 291,505 | +140.3% | 680,379 | 1.00 |
| 2024-10-31 | 121,295 | +46.5% | 171,200 | 1.00 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of ALGS volume is 17.1%, down 30.4 points over the last five sessions. Over the last 30 readings it ranged from 9.3% (28 October 2026) to 85.7% (12 October 2026). The latest reading is 31.2 points below the 30-session average of 48.3%, on 14K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 2K | 14K | 17.1% | 0 |
| 2026-10-30 | 9K | 16K | 57.2% | 0 |
| 2026-10-29 | 17K | 38K | 44.7% | 0 |
| 2026-10-28 | 1K | 14K | 9.3% | 100 |
| 2026-10-27 | 4K | 6K | 79.4% | 0 |
| 2026-10-26 | 9K | 20K | 47.5% | 0 |
| 2026-10-23 | 298 | 1K | 23.7% | 0 |
| 2026-10-22 | 2K | 3K | 69.7% | 0 |
| 2026-10-21 | 3K | 8K | 40.2% | 0 |
| 2026-10-20 | 12K | 19K | 63.1% | 0 |
| 2026-10-19 | 7K | 18K | 37.9% | 0 |
| 2026-10-16 | 8K | 22K | 35.2% | 0 |
| 2026-10-15 | 4K | 17K | 24.8% | 0 |
| 2026-10-14 | 10K | 18K | 55.6% | 626 |
| 2026-10-13 | 3K | 12K | 21.9% | 0 |
| 2026-10-12 | 27K | 32K | 85.7% | 0 |
| 2026-10-09 | 2K | 3K | 78.7% | 0 |
| 2026-10-08 | 5K | 11K | 49.8% | 0 |
| 2026-10-07 | 4K | 12K | 31.7% | 0 |
| 2026-10-06 | 1K | 6K | 22.6% | 5 |
| 2026-10-05 | 6K | 19K | 31.7% | 0 |
| 2026-10-02 | 5K | 11K | 47.8% | 0 |
| 2026-10-01 | 7K | 19K | 35.5% | 0 |
| 2026-09-30 | 8K | 17K | 50.5% | 0 |
| 2026-09-29 | 4K | 5K | 70.2% | 0 |
| 2026-09-28 | 9K | 26K | 33.4% | 0 |
| 2026-09-25 | 15K | 21K | 72.9% | 0 |
| 2026-09-24 | 15K | 24K | 60.4% | 0 |
| 2026-09-23 | 9K | 12K | 77.8% | 0 |
| 2026-09-22 | 32K | 44K | 71.8% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 13 October 2026, the fails-to-deliver balance in ALGS is 932 shares, up 464 shares over the last settlement date. Over the last 30 readings it ranged from 83 shares (29 September 2026) to 292,415 shares (10 August 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-13 | 932 | $5.53 | $5K |
| 2026-10-09 | 468 | $5.31 | $2K |
| 2026-10-08 | 835 | $5.32 | $4K |
| 2026-10-07 | 265 | $5.38 | $1K |
| 2026-10-06 | 1,382 | $5.40 | $7K |
| 2026-10-05 | 1,028 | $5.54 | $6K |
| 2026-10-02 | 432 | $5.50 | $2K |
| 2026-10-01 | 420 | $5.63 | $2K |
| 2026-09-30 | 90 | $5.62 | $506 |
| 2026-09-29 | 83 | $5.54 | $460 |
| 2026-09-28 | 3,012 | $5.51 | $17K |
| 2026-09-22 | 20,624 | $5.49 | $113K |
| 2026-09-08 | 106 | $6.21 | $658 |
| 2026-08-31 | 822 | $6.91 | $6K |
| 2026-08-25 | 216 | $6.93 | $1K |
| 2026-08-17 | 207 | $6.89 | $1K |
| 2026-08-14 | 207 | $6.77 | $1K |
| 2026-08-13 | 907 | $7.00 | $6K |
| 2026-08-11 | 207,684 | $7.65 | $1.6M |
| 2026-08-10 | 292,415 | $5.59 | $1.6M |
| 2026-08-07 | 106,196 | $5.51 | $585K |
| 2026-08-06 | 10,279 | $4.74 | $49K |
| 2026-08-05 | 8,728 | $4.75 | $41K |
| 2026-08-04 | 33,329 | $4.60 | $153K |
| 2026-08-03 | 13,273 | $4.23 | $56K |
| 2026-07-31 | 14,635 | $4.32 | $63K |
| 2026-07-29 | 1,078 | $4.25 | $5K |
| 2026-07-28 | 7,043 | $4.08 | $29K |
| 2026-07-27 | 5,221 | $4.08 | $21K |
| 2026-07-24 | 12,212 | $4.69 | $57K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for ALGS in the last 90 days. The most recent filings are listed below. Latest filing: Scopa James Paul (Director) on 2023-10-25.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2023-10-25 | Scopa James Paul | Director | Grant | 183K | $0.76 | $139K | 183K |
| 2023-10-25 | BLATT LAWRENCE | Chief Executive Officer | Grant | 610K | $0.76 | $464K | 1.8M |
| 2023-10-25 | Nuechterlein Carole | Director,TenPercentOwner | Buy | 7.9M | $0.76 | $6.0M | 11.0M |
| 2021-06-11 | Woiwode Thomas | Director | Other transaction | 8K | $0.00 | $0 | 8K |
| 2021-06-11 | Woiwode Thomas | Director | Other transaction | 10K | $0.00 | $0 | 0 |
| 2021-06-11 | Woiwode Thomas | Director | Other transaction | 10K | $0.00 | $0 | 10K |
| 2021-06-11 | Woiwode Thomas | Director | Other transaction | 2K | $0.00 | $0 | 4K |
| 2021-06-11 | Woiwode Thomas | Director | Other transaction | 8K | $0.00 | $0 | 0 |
| 2021-06-11 | Woiwode Thomas | Director | Other transaction | 486K | $0.00 | $0 | 1.5M |
| 2021-04-26 | Woiwode Thomas | Director | Other transaction | 8K | $0.00 | $0 | 8K |
| 2021-04-26 | Woiwode Thomas | Director | Other transaction | 10K | $0.00 | $0 | 10K |
| 2021-04-26 | Woiwode Thomas | Director | Other transaction | 486K | $0.00 | $0 | 1.9M |
| 2021-04-26 | Woiwode Thomas | Director | Other transaction | 10K | $0.00 | $0 | 0 |
| 2021-04-26 | Woiwode Thomas | Director | Other transaction | 8K | $0.00 | $0 | 0 |
| 2021-04-26 | Woiwode Thomas | Director | Other transaction | 2K | $0.00 | $0 | 2K |
| 2020-10-20 | BLATT LAWRENCE | Chief Executive Officer | Conversion | 1K | price not stated in the filing | not stated | 19K |
| 2020-10-20 | BLATT LAWRENCE | Chief Executive Officer | Conversion | 3K | price not stated in the filing | not stated | 17K |
| 2020-10-20 | BLATT LAWRENCE | Chief Executive Officer | Conversion | 14K | price not stated in the filing | not stated | 14K |
| 2020-10-20 | Beigelman Leonid | President | Conversion | 1K | price not stated in the filing | not stated | 18K |
| 2020-10-20 | Beigelman Leonid | President | Conversion | 3K | price not stated in the filing | not stated | 17K |
| 2020-10-20 | Beigelman Leonid | President | Conversion | 14K | price not stated in the filing | not stated | 14K |
| 2020-10-20 | Beigelman Leonid | President | Conversion | 22K | price not stated in the filing | not stated | 236K |
| 2020-10-20 | Beigelman Leonid | President | Conversion | 1K | price not stated in the filing | not stated | 18K |
| 2020-10-20 | Beigelman Leonid | President | Conversion | 3K | price not stated in the filing | not stated | 17K |
| 2020-10-20 | Beigelman Leonid | President | Conversion | 51K | price not stated in the filing | not stated | 215K |
| 2020-10-20 | Beigelman Leonid | President | Conversion | 14K | price not stated in the filing | not stated | 14K |
| 2020-10-20 | Beigelman Leonid | President | Conversion | 164K | price not stated in the filing | not stated | 164K |
| 2020-10-20 | BLATT LAWRENCE | Chief Executive Officer | Conversion | 41K | price not stated in the filing | not stated | 41K |
| 2020-10-20 | BLATT LAWRENCE | Chief Executive Officer | Conversion | 51K | price not stated in the filing | not stated | 92K |
| 2020-10-20 | BLATT LAWRENCE | Chief Executive Officer | Conversion | 14K | price not stated in the filing | not stated | 14K |
| 2020-10-20 | BLATT LAWRENCE | Chief Executive Officer | Conversion | 123K | price not stated in the filing | not stated | 123K |
| 2020-10-20 | BLATT LAWRENCE | Chief Executive Officer | Conversion | 3K | price not stated in the filing | not stated | 17K |
| 2020-10-20 | BLATT LAWRENCE | Chief Executive Officer | Conversion | 22K | price not stated in the filing | not stated | 113K |
| 2020-10-20 | BLATT LAWRENCE | Chief Executive Officer | Conversion | 1K | price not stated in the filing | not stated | 19K |
| 2020-10-20 | Nuechterlein Carole | Director | Conversion | 663K | price not stated in the filing | not stated | 2.8M |
| 2020-10-20 | Nuechterlein Carole | Director | Conversion | 284K | price not stated in the filing | not stated | 3.1M |
| 2020-10-20 | Nuechterlein Carole | Director | Conversion | 2.1M | price not stated in the filing | not stated | 2.1M |
| 2020-10-20 | Quan Lucinda Y. | See Remarks | Conversion | 2K | price not stated in the filing | not stated | 9K |
| 2020-10-20 | Quan Lucinda Y. | See Remarks | Conversion | 726 | price not stated in the filing | not stated | 9K |
| 2020-10-20 | Quan Lucinda Y. | See Remarks | Conversion | 7K | price not stated in the filing | not stated | 7K |
| 2020-10-20 | Symons Julian A. | See Remarks | Conversion | 1K | price not stated in the filing | not stated | 394K |
| 2020-10-20 | Symons Julian A. | See Remarks | Conversion | 3K | price not stated in the filing | not stated | 393K |
| 2020-10-20 | Symons Julian A. | See Remarks | Conversion | 14K | price not stated in the filing | not stated | 389K |
| 2020-10-20 | Versant Venture Capital VI, L.P. | TenPercentOwner | Conversion | 199K | price not stated in the filing | not stated | 2.3M |
| 2020-10-20 | Versant Venture Capital VI, L.P. | TenPercentOwner | Conversion | 464K | price not stated in the filing | not stated | 464K |
| 2020-10-20 | Versant Venture Capital VI, L.P. | TenPercentOwner | Conversion | 85K | price not stated in the filing | not stated | 2.4M |
| 2020-10-20 | Versant Venture Capital VI, L.P. | TenPercentOwner | Conversion | 198K | price not stated in the filing | not stated | 662K |
| 2020-10-20 | Versant Venture Capital VI, L.P. | TenPercentOwner | Conversion | 2.1M | price not stated in the filing | not stated | 2.1M |
| 2020-10-20 | Versant Venture Capital VI, L.P. | TenPercentOwner | Buy | 200K | $15.00 | $3.0M | 862K |
| 2020-10-20 | Vivo Capital Surplus Fund VIII, L.P. | TenPercentOwner | Conversion | 260K | price not stated in the filing | not stated | 260K |
| 2020-10-20 | Vivo Capital Surplus Fund VIII, L.P. | TenPercentOwner | Conversion | 1.9M | price not stated in the filing | not stated | 1.9M |
| 2020-10-20 | Vivo Capital Surplus Fund VIII, L.P. | TenPercentOwner | Buy | 483K | $15.00 | $7.2M | 3.1M |
| 2020-10-20 | Vivo Capital Surplus Fund VIII, L.P. | TenPercentOwner | Conversion | 31K | price not stated in the filing | not stated | 364K |
| 2020-10-20 | Vivo Capital Surplus Fund VIII, L.P. | TenPercentOwner | Conversion | 72K | price not stated in the filing | not stated | 333K |
| 2020-10-20 | Vivo Capital Surplus Fund VIII, L.P. | TenPercentOwner | Buy | 67K | $15.00 | $1.0M | 430K |
| 2020-10-20 | Vivo Capital Surplus Fund VIII, L.P. | TenPercentOwner | Conversion | 224K | price not stated in the filing | not stated | 2.6M |
| 2020-10-20 | Vivo Capital Surplus Fund VIII, L.P. | TenPercentOwner | Conversion | 524K | price not stated in the filing | not stated | 2.4M |
| 2020-10-20 | Woiwode Thomas | Director | Conversion | 198K | price not stated in the filing | not stated | 662K |
| 2020-10-20 | Woiwode Thomas | Director | Buy | 200K | $15.00 | $3.0M | 862K |
| 2020-10-20 | Woiwode Thomas | Director | Conversion | 85K | price not stated in the filing | not stated | 2.4M |
| 2020-10-20 | Woiwode Thomas | Director | Conversion | 2.1M | price not stated in the filing | not stated | 2.1M |
| 2020-10-20 | Woiwode Thomas | Director | Conversion | 199K | price not stated in the filing | not stated | 2.3M |
| 2020-10-20 | Woiwode Thomas | Director | Conversion | 464K | price not stated in the filing | not stated | 464K |
| 2020-10-20 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | TenPercentOwner | Conversion | 1.3M | price not stated in the filing | not stated | 1.3M |
| 2020-10-20 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | TenPercentOwner | Conversion | 571K | price not stated in the filing | not stated | 1.9M |
| 2020-10-20 | Novo Holdings A/S | TenPercentOwner | Buy | 200K | $15.00 | $3.0M | 2.6M |
| 2020-10-20 | Novo Holdings A/S | TenPercentOwner | Conversion | 2.4M | price not stated in the filing | not stated | 2.4M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON2 holders report 5% or more of ALGS in their latest filing, 1 on Schedule 13D (active intent). The largest reported stake is Lawrence M. Blatt at 5.6% of the class (316,228 shares), filed 2026-06-24 for an event on 2026-06-16.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-06-24 | 13D | Lawrence M. Blattindividual | 316K | 5.6% | 2026-06-16 |
| 2026-05-15 | 13G/Ano. 4 | Woodline Partners LPpartnership, individual | 239K | 4.4% | 2026-03-31 |
| 2026-02-11 | 13G/Ano. 1 | Sio Capital Management, LLCinvestment adviser | 336K | 5.5% | 2025-12-31 |
13F holders
Tracked managers holding ALGS at their latest 13F. JSON2 of the 30 tracked managers held ALGS at their latest 13F, $446K in total at quarter-end prices. D. E. Shaw & Co. is the largest at $383K (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 1 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| D. E. Shaw & Co. | 2026-06-30 | 66K | $383K | 0.00% | +55K |
| Renaissance Technologies | 2026-06-30 | 11K | $62K | 0.00% | -90K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Aligos Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Aligos Therapeutics (ALGS), SEC CIK 1799448, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-13.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-06-24.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2023-10-25.JSON and CSV
- Company record
- EDGAR filing index for CIK 1799448Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of ALGS is sold short?
707,471 shares were held short at the 2026-10-15 settlement, 21.7 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ALGS's daily short volume?
On 2026-11-02, 2,335 of the 13,667 ALGS shares reported to FINRA were sold short, 17.1% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ALGS have fails to deliver?
The SEC's latest file shows 932 ALGS shares failed to deliver at settlement 2026-10-13. Fails are reported per settlement date and published twice a month with a lag.
Are ALGS insiders buying or selling?
No open-market insider trades were reported for ALGS in the last 90 days. The most recent filings are listed below. Latest filing: Scopa James Paul (Director) on 2023-10-25.
Who owns 5% or more of ALGS?
2 holders report 5% or more of ALGS in their latest filing, 1 on Schedule 13D (active intent). The largest reported stake is Lawrence M. Blatt at 5.6% of the class (316,228 shares), filed 2026-06-24 for an event on 2026-06-16.
Which tracked 13F managers own ALGS?
2 of the 30 tracked 13F managers held ALGS shares at their latest filing, $446K in all. The largest: D. E. Shaw & Co. (66K shares, $383K), Renaissance Technologies (11K shares, $62K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.